It was recorded an increase on Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA)’s shares shorted with 7.54%. It was announced in November by FINRA the 38.79 million shares shorted on TEVA. The up change of 7.54% from 36.07 million shares was reported. 3 days will cost TEVA with 13.75M average volume to recover its former position. Float short on Teva Pharmaceutical Industries Limited American DE is 4.17%.
TEVA is touching $23.45 during the last trading session, after decreased 1.64%.Currently Teva Pharmaceutical Industries Limited is uptrending after 14.85% change in last November 10, 2017. TEVA has also 6.64M shares volume. The stock underperformed the S&P500 by 0.77%.
Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.The firm is worth $23.89 billion. It operates through two divisions, Generic Medicines and Specialty Medicines.Currently it has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage
Total analysts of 12 have positions in Teva Pharmaceutical Indus (NYSE:TEVA) as follows: 4 rated it a “Buy”, 1 with “Sell” and 7 with “Hold”. The positive are 33%. Since May 24, 2018 according to StockzIntelligence Inc Teva Pharmaceutical Indus has 17 analyst reports. The stock rating was upgraded by Wells Fargo to “Market Perform” on Monday, June 18. On Monday, September 17 the stock has “Neutral” rating by Credit Suisse. On Monday, November 5 the stock has “Overweight” rating by Morgan Stanley. On Monday, June 11 the firm has “Sell” rating by Leerink Swann given. On Thursday, May 24 the firm earned “Hold” rating by Guggenheim. On Monday, October 1 the rating was maintained by Goldman Sachs with “Buy”. On Thursday, May 31 the firm earned “Buy” rating by Citigroup. On Monday, August 6 Barclays Capital maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating. Barclays Capital has “Equal-Weight” rating and $23 target. On Monday, September 17 the firm earned “Neutral” rating by BTIG Research. On Monday, July 16 the firm earned “Neutral” rating by Cantor Fitzgerald.
For more Teva Pharmaceutical Industries Limited (NYSE:TEVA) news announced briefly go to: 247Wallst.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Seekingalpha.com. The titles are as follows: “The Drag on Teva’s Q3 Results” announced on November 01, 2018, “Morgan Stanley upgrades Teva and Bausch in premarket analyst action” on November 05, 2018, “4 Reasons To Buy Teva” with a publish date: November 02, 2018, “These 3 Value Stocks Are Absurdly Cheap Right Now” and the last “Teva Pharmaceutical beats by $0.13, misses on revenue” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.